TMCnet News
CymaBay Therapeutics Announces Departure of Chief Medical OfficerNEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that Pol Boudes, M.D., Chief Medical Officer, will be leaving the company on September 30, 2019 to explore other opportunities. CymaBay has initiated a formal search for his replacement. “Pol helped transition our focus to liver diseases and played a key role in advancing seladelpar to Phase 3 for patients with primary biliary cholangitis,” said Sujal Shah, President and Chief Executive Officer of CymaBay. “We thank Pol for his contributions over the past five years and wish him the best in his future endeavors.” Dr. Gideon Hirschfield, M.D. has been a close advisor to the company and will continue to provide key medical and clinical support to CymaBay. Dr. Hirschfield is the inaugural Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the Toronto Centre for Liver Disease (TCLD), Toronto General Hospital and Professor of Medicine in the Division of Gastroenterology at the University of Toronto. Dr. Hirschfield is a world-renowned autoimmune liver disease clinician-scientist with extensive clinical expertise i the management of complex liver disease and is now co-leading the Autoimmune Liver Disease Program at TCLD. About CymaBay For additional information about CymaBay visit www.cymabay.com. Contact: |